1100 13th Street, NW, Suite 1000Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2020The Kiplinger Washington Editors
These companies are well positioned to rebound next year.
This biotechnology giant has good growth drivers, but also a noteworthy drag on the stock.
A promising pipeline should mean continued success for the second-largest biotech firm, analysts say.
More Investing News »